查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1591981

免疫化學市場：按產品、來源、應用和最終用戶 - 2025-2030 年全球預測

Immunochemicals Market by Product (Antibodies, Cytokines & Chemokines, Immunoglobulins), Source (Animal-Derived, Synthetic), Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年免疫化學市場價值為29.2億美元，預計2024年將達31.2億美元，複合年成長率為7.19%，到2030年將達到47.5億美元。

免疫化學市場包括用於免疫學研究、診斷和治療的各種產品和物質。它的核心包括檢測和操縱免疫反應所必需的抗體、抗原、酵素和試劑。對免疫化學的需求是由旨在闡明免疫機制的科學研究的增加、對新興疾病的診斷需求的增加以及治療性抗體的擴大開發所推動的。治療應用涵蓋學術和臨床研究、生物技術和製藥業，最終用途為腫瘤學、感染疾病和自體免疫疾病治療，滿足廣泛的專業醫療需求。

主要市場統計
基準年[2023] 29.2億美元
預測年份 [2024] 31.2億美元
預測年份 [2030] 47.5億美元
複合年成長率（%） 7.19%

關鍵的成長要素包括抗體生產的技術進步、藥物研發投資的增加以及需要更精確的診斷和個人化醫療方法的慢性病的日益普及。此外，生技藥品和生物相似藥的技術創新正在開闢新的途徑，而新興市場的地理擴張則透過增加醫療基礎設施投資創造了新的機會。然而，市場成長並非沒有挑戰。複雜的監管環境、與研發相關的高成本以及專門的儲存和處理要求限制了更廣泛的市場滲透。

對於希望將這一前景廣闊的領域商業化的公司來說，最合適的創新領域包括開發具有更高特異性和更低免疫抗原性的單株抗體、用於即時診斷的生物感測器的進步以及免疫原性，其中包括提高抗體穩定性和保存期限的技術。與人工智慧在免疫學研究中進行資料分析的合作也很有前景，可以提供更大的洞察力和效率。儘管面臨挑戰，市場仍然充滿活力，預計將透過有針對性的創新和戰略區域多元化實現成長。公司應專注於尖端研究、具有成本效益的生產以及與研究和醫療機構的策略夥伴關係關係，以便在這個不斷變化的市場環境中取得成功。

市場動態：揭示快速發展的免疫化學市場的關鍵市場洞察

供需的動態交互作用正在改變免疫化學市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 活性化全球藥物發現與開發活動
    • 政府對免疫化學、基因組學和蛋白​​質組學研究的支持
    • 利用免疫化學技術進行疾病的早期檢測與診斷
  • 市場限制因素
    • 檢測套組有交叉污染的風險和潛在的假陽性結果
  • 市場機會
    • 研究免疫化學的先進製劑的興起
    • 採用奈米技術開發先進的臨床診斷檢測套組
  • 市場問題
    • 免疫化學生產和使用的嚴格監管指南

波特的五力：駕馭免疫化學市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解免疫化學市場的外部影響

外部宏觀環境因素在塑造免疫化學市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解免疫化學市場的競爭格局

對免疫化學市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV 定位矩陣：免疫化學市場供應商的績效評估

FPNV定位矩陣是評估免疫化學市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：規劃免疫化學市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，免疫化學市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地的藥物發現和開發活動增加
      • 政府對免疫化學、基因組學和蛋白​​質組學研究的支持
      • 利用免疫化學技術進行疾病的早期檢測與診斷
    • 抑制因素
      • 檢測套組交叉污染的風險和潛在的誤報
    • 機會
      • 推出研究免疫化學的先進配方
      • 利用奈米技術開發先進的臨床診斷檢測套組
    • 任務
      • 免疫化學生產和使用的嚴格監管指南
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章免疫化學市場：依產品

  • 介紹
  • 抗體
  • 細胞激素和趨化素
  • 免疫球蛋白

第7章免疫化學市場：依來源分類

  • 介紹
  • 動物起源
  • 合成

第8章免疫化學市場：依應用分類

  • 介紹
  • 自體免疫疾病
  • 感染疾病
  • 神經病學
  • 腫瘤學

第9章免疫化學市場：依最終用戶分類

  • 介紹
  • 生物技術和製藥公司
  • 臨床實驗室
  • 合約研究組織
  • 法醫學組織
  • 研究/學術機構

第10章美洲免疫化學市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太免疫化學市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲免疫化學市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbIoTec, Inc.
  • Abcam PLC
  • Active Motif Incorporated
  • Agilent Technologies, Inc.
  • AMS BIoTechnology（Europe）Limited.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Biocare Medical, LLC
  • BioGenex Laboratories
  • Biosynth Laboratories
  • BMA Biomedicals
  • Cayman Chemical
  • Cell Signaling Technology, Inc.
  • Creative Diagnostics
  • Danahar Corporation
  • Elabscience BIoTechnology Inc.
  • F. Hoffmann-La Roche Ltd
  • Fortis Life Sciences
  • GE Healthcare
  • Genemed BIoTechnologies, Inc.
  • GenScript BIoTech Corporation
  • Merck KGaA
  • Miltenyi BIoTech
  • MyBioSource
  • Origene Technologies Inc.
  • PerkinElmer, Inc.
  • Rockland Immunochemicals, Inc.
  • Santa Cruz BIoTechnology
  • Specifica Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-C002B1C994F8

The Immunochemicals Market was valued at USD 2.92 billion in 2023, expected to reach USD 3.12 billion in 2024, and is projected to grow at a CAGR of 7.19%, to USD 4.75 billion by 2030.

The immunochemicals market encompasses a range of products and substances used in immunological research, diagnostics, and therapeutics. At its core, it includes antibodies, antigens, enzymes, and reagents crucial for detecting and manipulating immune responses. The necessity for immunochemicals is driven by increasing scientific research aimed at understanding immune mechanisms, growing demand for diagnostics amidst emerging diseases, and expanding development of therapeutic antibodies. Applications span across academic and clinical research, biotechnology, and pharmaceutical industries, with end uses in oncology, infectious diseases, and autoimmune disorders treatment, serving both specialized and broad-based healthcare needs.

KEY MARKET STATISTICS
Base Year [2023] USD 2.92 billion
Estimated Year [2024] USD 3.12 billion
Forecast Year [2030] USD 4.75 billion
CAGR (%) 7.19%

Key growth factors include technological advancements in antibody production, rising investments in pharmaceutical R&D, and the expanding prevalence of chronic diseases requiring more precise diagnostics and personalized medicine approaches. Additionally, innovations in biologics and biosimilars are opening new pathways, while geographic expansion in emerging markets is presenting fresh opportunities due to increasing healthcare infrastructure investments. However, market growth is not without challenges; the complicated regulatory landscape, high costs associated with research and development, and the requirement for specialized storage and handling limit wider market penetration.

For businesses aiming to capitalize on this promising sector, the best innovation areas include the development of monoclonal antibodies with improved specificity and reduced immunogenicity, biosensor advancements for real-time diagnostics, and techniques to enhance the stability and shelf-life of immunochemical products. Also promising are collaborations with AI for data analysis in immunological research, offering greater insights and efficiencies. Despite the challenges, the market is dynamic with prospects for growth through targeted innovation and strategic geographic diversification. Firms should focus on cutting-edge research, cost-effective production, and strategic partnerships with research institutions and healthcare organizations to navigate and thrive in this evolving market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Immunochemicals Market

The Immunochemicals Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing drug discovery and development activities worldwide
    • Government support for immunochemistry, genomics, and proteomics research
    • Use of immunochemical techniques for early disease detection and diagnosis
  • Market Restraints
    • Risk of cross-contamination and possibilities of false positives in test kits
  • Market Opportunities
    • Rise of advanced formulations of immunochemical for research
    • Adoption of nanotechnology to develop advanced clinical diagnostic test kits
  • Market Challenges
    • Strict regulatory guidelines regarding the production and use of immunochemical

Porter's Five Forces: A Strategic Tool for Navigating the Immunochemicals Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Immunochemicals Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Immunochemicals Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Immunochemicals Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Immunochemicals Market

A detailed market share analysis in the Immunochemicals Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Immunochemicals Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Immunochemicals Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Immunochemicals Market

A strategic analysis of the Immunochemicals Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immunochemicals Market, highlighting leading vendors and their innovative profiles. These include Abbiotec, Inc., Abcam PLC, Active Motif Incorporated, Agilent Technologies, Inc., AMS Biotechnology (Europe) Limited., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocare Medical, LLC, BioGenex Laboratories, Biosynth Laboratories, BMA Biomedicals, Cayman Chemical, Cell Signaling Technology, Inc., Creative Diagnostics, Danahar Corporation, Elabscience Biotechnology Inc., F. Hoffmann-La Roche Ltd, Fortis Life Sciences, GE Healthcare, Genemed Biotechnologies, Inc., GenScript Biotech Corporation, Merck KGaA, Miltenyi Biotech, MyBioSource, Origene Technologies Inc., PerkinElmer, Inc., Rockland Immunochemicals, Inc., Santa Cruz Biotechnology, Specifica Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Immunochemicals Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Antibodies, Cytokines & Chemokines, and Immunoglobulins.
  • Based on Source, market is studied across Animal-Derived and Synthetic.
  • Based on Application, market is studied across Autoimmune Disease, Infectious Disease, Neurology, and Oncology.
  • Based on End-User, market is studied across Biotechnology & Pharmaceutical Companies, Clinical Laboratories, Contract Research Organizations, Forensic Organizations, and Research & Academic Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing drug discovery and development activities worldwide
      • 5.1.1.2. Government support for immunochemistry, genomics, and proteomics research
      • 5.1.1.3. Use of immunochemical techniques for early disease detection and diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. Risk of cross-contamination and possibilities of false positives in test kits
    • 5.1.3. Opportunities
      • 5.1.3.1. Rise of advanced formulations of immunochemical for research
      • 5.1.3.2. Adoption of nanotechnology to develop advanced clinical diagnostic test kits
    • 5.1.4. Challenges
      • 5.1.4.1. Strict regulatory guidelines regarding the production and use of immunochemical
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Immunochemicals Market, by Product

  • 6.1. Introduction
  • 6.2. Antibodies
  • 6.3. Cytokines & Chemokines
  • 6.4. Immunoglobulins

7. Immunochemicals Market, by Source

  • 7.1. Introduction
  • 7.2. Animal-Derived
  • 7.3. Synthetic

8. Immunochemicals Market, by Application

  • 8.1. Introduction
  • 8.2. Autoimmune Disease
  • 8.3. Infectious Disease
  • 8.4. Neurology
  • 8.5. Oncology

9. Immunochemicals Market, by End-User

  • 9.1. Introduction
  • 9.2. Biotechnology & Pharmaceutical Companies
  • 9.3. Clinical Laboratories
  • 9.4. Contract Research Organizations
  • 9.5. Forensic Organizations
  • 9.6. Research & Academic Institutes

10. Americas Immunochemicals Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Immunochemicals Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Immunochemicals Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbiotec, Inc.
  • 2. Abcam PLC
  • 3. Active Motif Incorporated
  • 4. Agilent Technologies, Inc.
  • 5. AMS Biotechnology (Europe) Limited.
  • 6. Becton, Dickinson and Company
  • 7. Bio-Rad Laboratories, Inc.
  • 8. Bio-Techne Corporation
  • 9. Biocare Medical, LLC
  • 10. BioGenex Laboratories
  • 11. Biosynth Laboratories
  • 12. BMA Biomedicals
  • 13. Cayman Chemical
  • 14. Cell Signaling Technology, Inc.
  • 15. Creative Diagnostics
  • 16. Danahar Corporation
  • 17. Elabscience Biotechnology Inc.
  • 18. F. Hoffmann-La Roche Ltd
  • 19. Fortis Life Sciences
  • 20. GE Healthcare
  • 21. Genemed Biotechnologies, Inc.
  • 22. GenScript Biotech Corporation
  • 23. Merck KGaA
  • 24. Miltenyi Biotech
  • 25. MyBioSource
  • 26. Origene Technologies Inc.
  • 27. PerkinElmer, Inc.
  • 28. Rockland Immunochemicals, Inc.
  • 29. Santa Cruz Biotechnology
  • 30. Specifica Inc.
  • 31. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. IMMUNOCHEMICALS MARKET RESEARCH PROCESS
  • FIGURE 2. IMMUNOCHEMICALS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IMMUNOCHEMICALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS IMMUNOCHEMICALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS IMMUNOCHEMICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES IMMUNOCHEMICALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES IMMUNOCHEMICALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC IMMUNOCHEMICALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC IMMUNOCHEMICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA IMMUNOCHEMICALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA IMMUNOCHEMICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. IMMUNOCHEMICALS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. IMMUNOCHEMICALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IMMUNOCHEMICALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IMMUNOCHEMICALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. IMMUNOCHEMICALS MARKET DYNAMICS
  • TABLE 7. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY CYTOKINES & CHEMOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY ANIMAL-DERIVED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY AUTOIMMUNE DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY FORENSIC ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNOCHEMICALS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS IMMUNOCHEMICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES IMMUNOCHEMICALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC IMMUNOCHEMICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA IMMUNOCHEMICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM IMMUNOCHEMICALS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM IMMUNOCHEMICALS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM IMMUNOCHEMICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM IMMUNOCHEMICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. IMMUNOCHEMICALS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. IMMUNOCHEMICALS MARKET, FPNV POSITIONING MATRIX, 2023